Advanced Formulations 1 Flashcards

1
Q

Peptide drug vs protein drugs

A

-amino acids make peptides (>50aa) make proteins 2’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Basic structure of amino acid

A

-NH2 AMINO group
-COOH ACID group
-link w peptide bonds C-N

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Semaglutide Ozempic

A

-synthetic
-31 aa
-weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Peptide drug synthesis

A
  1. porous bead of NH2 functional groups
  2. coupling w aa w PG
  3. Deprotection (remove PG)
  4. Coupling w aa w PG
  5. Deprotection
  6. Cleavage (remove bead) or more cylcles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Problems w peptide drug synthesis

A

-coupling yields need to be very high for long synthesis
-yields for consecutive reactions need to be multiplied

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Linear yield math

A

-if 80% for 5 aa
-0.8^5 = 0.328 = 32.8% overall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

convergent synthesis yield math

A

-yield of just one of them but steps are going on at the same time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Yield of linear peptide 31 aa with 90% yield each step

A

-(0.9)^31 = 0.038 = 3.8%
-very low

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

protein size

A

greater than 40 aa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Can biologics be compounded?

A

-NO
-too fragile
-denaturation, aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Protein drugs

A

-BIG >1000aa
-too hard to synthesize in lab
-v complex v fragile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are protein drugs produced?

A

-100-1000L
-pilot plant
-probes for pH, dissolved O2, temp, pressure, biomass, carbon source

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Basics of cloning/expression

A

-gene encoding protein drugs
-replication origin
-ampicillin resistance
-plasmid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Protein drug biosynthesis

A

-cloning?
-ribosomal synthesis
-post-trans mods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Bacteria expression systems

A

-no glycosylation
-endotoxins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chinese hamster ovary

A

-expensive, susceptible to contamination w human pathogens/oncogenes
-best for antibody protection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Post translational modifications

A

-glycosylation adding extra sugars to the drug
-small differences can cause immune response
-careful process analytical tech to prove similarity of batched

18
Q

Gold standard to analyze protein drugs biosimilarity

A

-HPLC + mass spectrometry
-endoglycosidase cuts of glycosylation

19
Q

disulfide bonds can be unstable

A

lead to degradation

20
Q

Conditions that can lead to protein degradation

A

-temp
-agitation
-pH
-deamidation
-oxidation
-photostability

21
Q

Agitation leads to

A

-inc contact w surfaces
=aggregation
-do NOT shake

22
Q

Freezing leads to

A

-ice crystals
=more concentrated mAb solution
=aggregation

23
Q

Aggregation onset

A

-can happen hours after shaking

24
Q

Biologics stabilization

A

-excipients
-interact w surface of protein
-excluded: repell from protein raise energy
-bound: lower energy

25
Unfolded proteins
-higher Gibbs free enrgy -large surface area -more unstable
26
preferentially excluded excipients
-repelled from protein surface -raise energy -destabilizer
27
preferentially bound excipients
-bind to protein surface -lower energy -stabilize
28
Salt concentration effect on protein stability
-effect can be dif for dif proteins -unpreditable -NEVER compound biologics
29
Nature can store proteins
-very long time inside of sugar glass -Trehalose -old wise shrimp
30
Sugar glass
-Trehalose, water, protein -slow degradation bc high viscosity -frozen out motions = stability -biomimicry for storage of biologics
31
Blincyto
-reconstitute bc has trehalose for stability
32
Derivatization
-hydrophobic tail binds albumin =inc half life -levemir and ozempic (7day half life)
33
Considerations
-potency: nasal and pulmonary routes only for high potent drugs bc limited capacity -variability: high -safety -cost
34
Oral semaglutide
-qd -fasting required -low bioavailability 1% -does not open tight junctions
35
key challenge w RNA
-stability -extra OH than DNA so less stable -cleaved RNA can be toxic
36
siRNA
-30na -can be synthesized chemically -structure mods to inc half life
37
Longer RNAs synthesized by
-transciption enzymes -outside of cell -more controllable -isolate enzymes
38
Modification of nucleotides
-replace w Me -reduce immune reaction to mRNA -inc protein production
39
siRNA length
-much shorter -not transcribed to protein
40
Common RNA mods to ribose part
-me -F -OCCOC -eliminate the nucleophilic 2-OH =inc stability
41
Targeting ligands attached to the 3' or 5' ends of RNA can
-extend half-life of siRNAs -acetyl group helps target the liver
42
siRNA product
-Leqvio -injection every 3 to 6 MONTHS -lowers cholesterol levels -siRNA is very modified